Scientists test six new drug cocktails in race to improve melanoma treatment
NCT ID NCT04303169
Summary
This study tested six different drug combinations in people with Stage III melanoma who were scheduled for surgery. The goal was to see if adding new experimental drugs to a standard immunotherapy (pembrolizumab) could shrink tumors more effectively and safely before the operation. Researchers measured how many participants had their tumors completely disappear and tracked side effects to find the best future treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A.P.H. Paris, Hopital Saint Louis ( Site 3107)
Paris, 75010, France
-
CHUV Centre Hospitalier Universitaire Vaudois ( Site 3602)
Lausanne, Canton of Vaud, 1011, Switzerland
-
Centre Hospitalier Lyon Sud ( Site 3102)
Pierre-Bénite, Rhone, 69495, France
-
Chaim Sheba Medical Center ( Site 3701)
Ramat Gan, 5265601, Israel
-
Duke Cancer Institute ( Site 3005)
Durham, North Carolina, 27710, United States
-
Fiona Stanley Hospital ( Site 3401)
Murdoch, Western Australia, 6150, Australia
-
Gustave Roussy ( Site 3101)
Villejuif, Île-de-France Region, 94805, France
-
HaEmek Medical Center ( Site 3703)
Afula, 1834111, Israel
-
Hadassah Ein Karem Jerusalem ( Site 3702)
Jerusalem, 9112001, Israel
-
Hopital La Timone ( Site 3103)
Marseille, Bouches-du-Rhone, 13005, France
-
Hôpitaux Universitaires de Genève (HUG)-Oncology ( Site 3603)
Geneva, Canton of Geneva, 1211, Switzerland
-
Inova Schar Cancer Institute ( Site 3011)
Fairfax, Virginia, 22031, United States
-
Institut Claudius Regaud ( Site 3105)
Toulouse, Haute-Garonne, 31059, France
-
Istituto Europeo di Oncologia ( Site 3301)
Milan, 20141, Italy
-
Martha Morehouse Tower ( Site 3020)
Columbus, Ohio, 43221, United States
-
Melanoma Institute Australia ( Site 3402)
Wollstonecraft, New South Wales, 2065, Australia
-
NYU Clinical Cancer Center ( Site 3002)
New York, New York, 10016, United States
-
Oregon Health & Science University ( Site 3013)
Portland, Oregon, 97239, United States
-
Policlinico Le Scotte - A.O. Senese ( Site 3377)
Siena, 53100, Italy
-
Providence Saint John's Health Center ( Site 3010)
Santa Monica, California, 90404, United States
-
Rabin Medical Center-Oncology ( Site 3705)
Petah Tikva, 4941492, Israel
-
Rambam Health Care Campus-Oncology ( Site 3704)
Haifa, 3109601, Israel
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 3022)
Baltimore, Maryland, 21287, United States
-
Tasman Oncology Research Pty Ltd ( Site 3403)
Southport, Queensland, 4215, Australia
-
The Angeles Clinic and Research Institute ( Site 3009)
Los Angeles, California, 90025, United States
-
Universitaetsspital Zuerich ( Site 3601)
Zuerich Flughafen, Canton of Zurich, 8058, Switzerland
-
University of Colorado, Anschutz Cancer Pavilion ( Site 3012)
Aurora, Colorado, 80045, United States
-
University of Pennsylvania Abramson Cancer Center ( Site 3008)
Philadelphia, Pennsylvania, 19104, United States
-
West Cancer Center - East Campus ( Site 3014)
Germantown, Tennessee, 38138, United States
Conditions
Explore the condition pages connected to this study.